Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Patient-derived luminal breast cancer xenografts with progestins

ABSTRACT: Patient-derived luminal breast cancer xenografts with progestins

PROVIDER: PRJNA360064 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5138740.fastq.gz	Fastqsanger.gz
	SRR5138741.fastq.gz	Fastqsanger.gz
	SRR5138742.fastq.gz	Fastqsanger.gz
	SRR5138743.fastq.gz	Fastqsanger.gz
	SRR5138744.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

ChIPseq analysis of patient-derived luminal breast cancer xenografts with progestins

Project description:Primary breast cancer xenografts

2017-01-04 | GSE93108 | GEO

scRNA-seq analysis of patient-derived luminal breast cancer xenografts

Project description:scRNA-seq analysis of patient-derived luminal breast cancer xenografts

| PRJNA561776 | ENA

RNAseq analysis of patient-derived luminal breast cancer xenografts treated with progestins

Project description:Primary breast cancer xenografts

2017-01-04 | GSE93057 | GEO

Patient-derived luminal breast cancer xenografts with progestins

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-01-04 | GSE93109 | GEO

RNAseq analysis of cell lines established from patient-derived luminal breast cancer xenografts

Project description:RNAseq analysis of cell lines established from patient-derived luminal breast cancer xenografts

| PRJNA609071 | ENA

Thoracic patient-derived xenografts

Project description:Thoracic patient-derived xenografts

| PRJNA339191 | ENA

Patient-derived Human Breast Cancer Xenografts

Project description:Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that reflect patient tumor biology accurately. To overcome these limitations, we propagated a cohort of human breast tumors grown in the epithelium-free mammary fat pad of SCID/Beige and NOD/SCID/IL2γ-receptor null (NSG) mice, under a series of transplant conditions. Both models yielded stably transplantable xenografts at comparably high rates (~23% and ~19%, respectively). Of the conditions tested, xenograft take rate was highest in the presence of a low-dose estradiol pellet. Overall, 32 stably transplantable xenograft lines were established, representing unique 25 patients. Most tumors yielding xenografts were “triple-negative” (ER-PR-HER2+) (n=19). However, we established lines from three ER-PR-HER2+ tumors, one ER+PR-HER2-, one ER+PR+HER2- and one “triple-positive” (ER+PR+HER2+) tumor. Serially passaged xenografts show biological consistency with the tumor of origin, are phenotypic stability across multiple transplant generations at the histological, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses. Xenografts representing 12 patients, including two ER+ lines, showed metastasis to the mouse lung. These models thus serve as a renewable, quality-controlled tissue resource for preclinical studies investigating treatment response and metastasis. The study was designed to determine how stable patient-derived xenografts are across multiple transplant generations in mice, and to determine how closely xenografts established with pre-treatment samples cluster with xenografts established with post-treatment samples. Overall, pre-treatment and post-treatment samples derived from the same patient cluster together, and multiple transplant generations of xenografts derived from an individual patient cluster together.

2013-05-30 | E-GEOD-46106 | biostudies-arrayexpress

Estrogen and progesterone receptor dynamics in patient-derived luminal breast cancer xenografts

Project description:Progesterone receptors (PR) are co-expressed in over half of estrogen receptor (ER) positive breast cancers and predict positive response to endocrine therapy. PR can directly and globally modify ER action to attenuate tumor growth. However, whether this suppression occurs solely through PR-ER interactions remains unknown. We assessed tumor growth in two highly ER and PR positive breast cancer patient-derived xenografts (PDX) and found that natural and synthetic progestins potently antagonize the mitogenic effects of estrogens. Here we probed the genome-wide mechanisms by which this occurs. Chronic progestin treatment reversed expression of up to half of estrogen up- and downregulated genes at the transcript level. However, fewer than a quarter of ER DNA binding events were altered by progesterone. The PR cistrome showed an interesting bimodal distribution. In the first group, more than half of PR binding sites were co-occupied by ER, with a propensity for both receptors to coordinately gain or lose binding in the presence of progesterone. In the second group, PR, but not ER, was associated with a large fraction of RNA polymerase III (Pol III)-transcribed tRNA genes regardless of hormone treatment. Furthermore, PR formed a physical association with the Pol III holoenzyme. Select tRNAs with colocalization of PR and POLR3A at their promoters were reduced in tumors grown with estrogen plus progestin compared to estrogen alone. These data uncover a mechanism in solid tumors by which PR modulates the bioavailability of translational molecules that are necessary for robust tumor growth, which could indirectly impede ER action.

2017-02-28 | GSE93944 | GEO

Estrogen receptor dynamics in diverse patient-derived luminal breast cancer xenografts

Project description:Primary breast cancer xenografts Two primary xenografts with different treatments

2013-02-24 | E-GEOD-36075 | biostudies-arrayexpress

scRNA-seq analysis of patient-derived luminal breast cancer xenografts

Project description:Primary breast cancer xenografts

2022-08-12 | GSE136260 | GEO